Stefan Siemer

Dr. Stefan Siemer


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
FRFrederik C Roos
Frederik C Roos
SSSandra Steffens
Sandra Steffens
KJKerstin Junker
Kerstin Junker
MJMartin Janssen
Martin Janssen
FBFrank Becker
Frank Becker
FNFor The German Renal Cell Cancer Network
For The German Renal Cell Cancer Network
Partial nephrectomy (PN) preserves renal function and has become the standard approach for T1a renal cell carcinoma (RCC). However, there is still an ongoing debate as to which patients will actually derive greater benefit from partial than from radical nephrectomy (RN). The aim of this study was to retrospectively evaluate the impact of the type of surgery on overall survival (OS) in patients with localized RCC. Renal surgery was performed in 4326 patients with localized RCC (pT ≤ 3a N/M0) at six German tertiary care centers from 1980 to 2010: RN in 2955 cases (68.3%), elective (ePN) in 1108 (25.6%), and imperative partial nephrectomy (iPN) in 263 (6.1%) cases. The median follow-up for all patients was 63 months. Kaplan-Meier and Cox regression analyses were carried out to identify prognosticators for OS. PN was performed significantly more often than RN in patients presenting with lower tumor stages, higher RCC differentiation, and non-clear cell histology. Accordingly, the calculated 5 (10)-year OS rates were 90.0 (74.6)% for ePN, 83.9 (57.5)% for iPN, and 81.2 (64.7)% for RN (p < 0.001). However, multivariate analysis including age, sex, tumor diameter and differentiation, histological subtype, and the year of surgery showed that ePN compared to RN still qualified as an independent factor for improved OS (HR 0.79, 95% CI 0.66-0.94, p = 0.008). Even allowing for the weaknesses of this retrospective analysis, our multicenter study indicates that in patients with localized RCC, PN appears to be associated with better OS than RN irrespective of age or tumor size.

Verified
Journal Article
Open access
PDF file
PZPhilip Zeuschner
Philip Zeuschner
LHLinda Hennig
Linda Hennig
RPRobert Peters
Robert Peters
MSMatthias Saar
Matthias Saar
JLJohannes Linxweiler
Johannes Linxweiler
FFFrank Friedersdorff
Frank Friedersdorff
Living kidney donation is the best treatment for end-stage renal disease, however, the best surgical approach for minimally-invasive donor nephrectomy (DN) is still a matter of debate. This bi-centric study aimed to retrospectively compare perioperative outcomes and postoperative kidney function after 257 transperitoneal DNs including 52 robot-assisted (RDN) and 205 laparoscopic DNs (LDN). As primary outcomes, the intraoperative (operating time, warm ischemia time (WIT), major complications) and postoperative (length of stay, complications) results were compared. As secondary outcomes, postoperative kidney and graft function were analyzed including delayed graft function (DGF) rates, and the impact of the surgical approach was assessed. Overall, the type of minimally-invasive donor nephrectomy (RDN vs. LDN) did not affect primary outcomes, especially not operating time and WIT; and major complication and DGF rates were low in both groups. A history of smoking and preoperative kidney function, but not the surgical approach, were predictive for postoperative serum creatinine of the donor and recipient. To conclude, RDN and LDN have equivalent perioperative results in experienced centers. For this reason, not the surgical approach, but rather the graft- (preoperative kidney function) and patient-specific (history of smoking) aspects impacted postoperative kidney function.

20 February 2018 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
MJMartin W. W. Janssen
Martin W. W. Janssen
JLJohannes Linxweiler
Johannes Linxweiler
IPInes Philipps
Ines Philipps
ZBZentia Bütow
Zentia Bütow
SSStefan Siemer
Stefan Siemer
COCarsten-Henning Ohlmann
Carsten-Henning Ohlmann
Kidney autotransplantation (KAT) is the ultimate approach for nephron-sparing surgery. It is a rarely used method in renal tumor surgery today as minimal invasive and open techniques for nephron-sparing surgery improve constantly. In this publication, the complication rate and the long-term functional and oncological outcome at a single center are analyzed. A prospectively constructed database of patients with renal tumors who underwent renal surgery was retrospectively analyzed to identify patients with KAT and describe surgical and oncological outcomes and to obtain long-term follow-up. Data collection included detailed surgical technique, complications (Clavian-Dindo), and hospital stay, as well as functional and oncological outcome and long-term follow-up. Between 1976 and 2013, 12 patients (median age 50.5 years) underwent KAT for highly complex renal masses: in five cases for complex renal cell carcinoma (RCC), five cases for complex upper urinary tract carcinoma (UTUC), one case for a renal metastasis, and one case for nephroblastoma. The nephrectomy or nephron-ureterectomy was performed open via a flank or transabdominal. The median surgical time was 360 min (range 270–490 min). Intraoperatively, six cases required blood transfusions (50%). Six patients (50%) developed significant postoperative complications (Clavian-Dindo > 2). In two patients, intermittent hemodialysis for delayed graft function (16.6%) was needed, and in six cases (50%), additional blood transfusions postoperatively were necessary. At discharge from hospital, all patients had functioning grafts. The median hospital stay was 29.5 days (range 18–35). At follow-up (median follow-up of 83.5 ± 40.7 months), six patients had died (50%)—all with functioning grafts (free from hemodialysis). In five cases, recurrence of primary tumor or metastatic disease was recorded. In four cases, the recurrent carcinoma could be resected; in detail, UTUC in three cases and one partial nephrectomy of the autotransplanted kidney was performed. One patient suffered from bone and lung metastasis. Two patients died finally tumor-related. Five patients (41.6%) are presently alive, without evidence of tumor relapse. One patient developed terminal renal failure requiring hemodialysis 105 months after autotransplantation. One additional patient was lost to follow-up; after 69 months, this patient had a functioning kidney and no evidence of disease-recurrence at the last follow-up. A cumulative number of 1424 months without hemodialysis was gained for these 12 patients. In the literature to date, most KAT are performed in benign disease, with minor but frequent complication. Here, we report the largest series of KAT for malignant kidney tumors. The complication rates are similar, compared to the recently reported series for benign indications with an improved graft survival rate. Since KAT requires a complex and challenging surgical approach, it should be performed by experienced kidney transplant surgeons. In very complex cases involving renal tumors and multi-morbidity, patients should be counseled well before KAT is considered. At the same time, KAT should not be abandoned in these very rare cases, especially when a nephron-sparing approach is otherwise not feasible. KAT can maintain renal function and quality of life and extend expectancy of life.

1 September 2021 in Surgical Oncology
Verified
Journal Article
Closed access
PZPhilip Zeuschner
Philip Zeuschner
SVSarah Grosse Vollmer
Sarah Grosse Vollmer
JLJohannes Linxweiler
Johannes Linxweiler
GWGudrun Wagenpfeil
Gudrun Wagenpfeil
SWStefan Wagenpfeil
Stefan Wagenpfeil
JHJulia Heinzelbecker
Julia Heinzelbecker

12 March 2001 in Der Urologe
Verified
Journal Article
Closed access
PDF file
SSStefan Siemer
Stefan Siemer
MUM. Uder
M. Uder
AZA. Zell
A. Zell
CPC. Pönicke
C. Pönicke
UHU. Humke
U. Humke
MSM. Stöckle
M. Stöckle

1 June 2018 in Surgical Oncology
Verified
Journal Article
Closed access
JLJohannes Linxweiler
Johannes Linxweiler
MSMatthias Saar
Matthias Saar
ZAZaid Al-Kailani
Zaid Al-Kailani
MJMartin Janssen
Martin Janssen
Samer EzziddinSamer Ezziddin
Samer Ezziddin
COCarsten-Henning Ohlmann
Carsten-Henning Ohlmann